The manufacturing records for onxaap-25 sn (b)(6) were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.All lots passed functional testing and met release specifications.An onxaap - 25 with serial number (b)(6) was implanted on (b)(6) 2022 in a 52-year-old female with a past medical history of a bicuspid aortic valve and an aortic root dilation of 45mm.The subject was enrolled in the ascend study.On (b)(6) 2023 (136 days post implant) the patient presented with complaints of dysarthria and motor aphasia, a nihss stroke scale was performed with a score of 0.Further testing was completed to include a ct of the head, ct angio of the brain and ekg.The ct angio showed left distal m2 occlusion, and the ekg showed sinus rhythm with left bundle branch block (known).Her inr level was 1.47 upon admission and she was given additional anticoagulation in the form of lmwh (low molecular weight heparin).The event was given an end date of (b)(6) 2023 (13 days) and it was classified as resolved without sequelae.The discharge diagnosis given was: left distal m2 occlusion with embolic mechanism and cardioembolic etiology due to under coagulation.Thromboembolism is recognized as a potential adverse event in the instructions for use [ifu] and occurs at a historical rate of 1.6 %/valve-year for mechanical aortic valves [iso 5840].According to the treating physician the root cause of the thromboembolism was under coagulation, supported by an inr of 1.47 at admission.No further action is required.This report is being submitted as required by federal regulations and does not constitute an admission that the device caused or contributed to the reported event.Furthermore, this report reflects the event as alleged by the complainant and does not imply that the information reported to artivion is accurate or has been confirmed by artivion.
|